Twenty years of evolution of CML therapy: how the treatment goal is moving from disease to patient
D Russo, M Malagola, N Polverelli… - Therapeutic …, 2023 - journals.sagepub.com
The introduction of imatinib in 2000 opened the era of tyrosine kinase inhibitors (TKIs) for
CML therapy and has revolutionized the life expectancy of CML patients, which is now quite …
CML therapy and has revolutionized the life expectancy of CML patients, which is now quite …
Twenty years of evolution of CML therapy: how the treatment goal is moving from disease to patient
D Russo, M Malagola, N Polverelli… - Therapeutic …, 2023 - pubmed.ncbi.nlm.nih.gov
The introduction of imatinib in 2000 opened the era of tyrosine kinase inhibitors (TKIs) for
CML therapy and has revolutionized the life expectancy of CML patients, which is now quite …
CML therapy and has revolutionized the life expectancy of CML patients, which is now quite …
[HTML][HTML] Twenty years of evolution of CML therapy: how the treatment goal is moving from disease to patient
D Russo, M Malagola, N Polverelli… - Therapeutic …, 2023 - ncbi.nlm.nih.gov
The introduction of imatinib in 2000 opened the era of tyrosine kinase inhibitors (TKIs) for
CML therapy and has revolutionized the life expectancy of CML patients, which is now quite …
CML therapy and has revolutionized the life expectancy of CML patients, which is now quite …
Twenty years of evolution of CML therapy: how the treatment goal is moving from disease to patient.
D Russo, M Malagola, N Polverelli… - Therapeutic …, 2023 - europepmc.org
The introduction of imatinib in 2000 opened the era of tyrosine kinase inhibitors (TKIs) for
CML therapy and has revolutionized the life expectancy of CML patients, which is now quite …
CML therapy and has revolutionized the life expectancy of CML patients, which is now quite …
Twenty years of evolution of CML therapy: how the treatment goal is moving from disease to patient
D Russo, M Malagola, N Polverelli, M Farina… - THERAPEUTIC …, 2023 - iris.unibs.it
: The introduction of imatinib in 2000 opened the era of tyrosine kinase inhibitors (TKIs) for
CML therapy and has revolutionized the life expectancy of CML patients, which is now quite …
CML therapy and has revolutionized the life expectancy of CML patients, which is now quite …
Twenty years of evolution of CML therapy: how the treatment goal is moving from disease to patient.
D Russo, M Malagola, N Polverelli… - Therapeutic …, 2023 - europepmc.org
The introduction of imatinib in 2000 opened the era of tyrosine kinase inhibitors (TKIs) for
CML therapy and has revolutionized the life expectancy of CML patients, which is now quite …
CML therapy and has revolutionized the life expectancy of CML patients, which is now quite …